Acorda Therapeutics, Inc. (ACOR): Price and Financial Metrics

Acorda Therapeutics, Inc. (ACOR): $0.61

-0.01 (-1.20%)

POWR Rating

Component Grades













Add ACOR to Watchlist
Sign Up

Industry: Biotech



in industry

ACOR Stock Summary

  • ACOR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.22 -- higher than only 2.66% of US-listed equities with positive expected earnings growth.
  • In terms of volatility of its share price, ACOR is more volatile than 97.54% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ACOR comes in at 465.43% -- higher than that of 99.33% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ACORDA THERAPEUTICS INC, a group of peers worth examining would be HAYW, NXTP, CIXX, MODV, and CBD.
  • Visit ACOR's SEC page to see the company's official filings. To visit the company's web site, go to

ACOR Valuation Summary

  • In comparison to the median Healthcare stock, ACOR's EV/EBIT ratio is 135.53% lower, now standing at -2.7.
  • Over the past 204 months, ACOR's price/earnings ratio has gone up 1.9.

Below are key valuation metrics over time for ACOR.

Stock Date P/S P/B P/E EV/EBIT
ACOR 2022-11-01 0.2 0.2 -0.2 -2.7
ACOR 2022-10-31 0.2 0.3 -0.2 -2.8
ACOR 2022-10-28 0.1 0.2 -0.1 -2.7
ACOR 2022-10-27 0.1 0.2 -0.1 -2.6
ACOR 2022-10-26 0.1 0.1 -0.1 -2.6
ACOR 2022-10-25 0.1 0.1 -0.1 -2.6

ACOR Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -353.06%.
  • Its 2 year revenue growth rate is now at -30.41%.
  • Its 3 year revenue growth rate is now at -70.02%.
ACOR's revenue has moved down $397,593,000 over the prior 67 months.

The table below shows ACOR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 122.008 -33.923 -118.842
2022-03-31 122.742 -28.097 -95.024
2021-12-31 129.071 -41.348 -103.954
2021-09-30 130.263 -43.14 -166.434
2021-06-30 151.897 -37.033 -132.016
2021-03-31 153.73 -49.115 -126.573

ACOR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACOR has a Quality Grade of C, ranking ahead of 72.56% of graded US stocks.
  • ACOR's asset turnover comes in at 0.251 -- ranking 176th of 680 Pharmaceutical Products stocks.
  • BDSI, INVA, and CALA are the stocks whose asset turnover ratios are most correlated with ACOR.

The table below shows ACOR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.251 0.695 -0.414
2021-03-31 0.232 0.729 -0.327
2020-12-31 0.217 0.781 -0.207
2020-09-30 0.221 0.810 0.173
2020-06-30 0.202 0.830 -0.419
2020-03-31 0.194 0.831 -0.393

ACOR Price Target

For more insight on analysts targets of ACOR, see our ACOR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.5 (Moderate Buy)

ACOR Stock Price Chart Interactive Chart >

Price chart for ACOR

ACOR Price/Volume Stats

Current price $0.61 52-week high $3.10
Prev. close $0.62 52-week low $0.26
Day low $0.60 Volume 45,400
Day high $0.63 Avg. volume 1,630,961
50-day MA $0.52 Dividend yield N/A
200-day MA $0.86 Market Cap 14.80M

Acorda Therapeutics, Inc. (ACOR) Company Bio

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company was founded in 1995 and is based in Ardsley, New York.

ACOR Latest News Stream

Event/Time News Detail
Loading, please wait...

ACOR Latest Social Stream

Loading social stream, please wait...

View Full ACOR Social Stream

Latest ACOR News From Around the Web

Below are the latest news stories about ACORDA THERAPEUTICS INC that investors may wish to consider to help them evaluate ACOR as an investment opportunity.

Acorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics ( NASDAQ:ACOR ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.5m (up 6.5% from 3Q...

Yahoo | November 19, 2022

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

PEARL RIVER, N.Y., November 11, 2022--Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

Yahoo | November 11, 2022

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

PEARL RIVER, N.Y., November 04, 2022--Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Yahoo | November 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | November 1, 2022

Acorda Therapeutics Reports Third Quarter 2022 Financial Results

PEARL RIVER, N.Y., November 01, 2022--Acorda Therapeutics Reports Third Quarter 2022 Financial Results

Yahoo | November 1, 2022

Read More 'ACOR' Stories Here

ACOR Price Returns

1-mo -6.87%
3-mo 49.11%
6-mo 19.82%
1-year -78.67%
3-year -94.19%
5-year -99.49%
YTD -74.48%
2021 -42.28%
2020 -66.17%
2019 -86.91%
2018 -27.37%
2017 14.10%

Continue Researching ACOR

Here are a few links from around the web to help you further your research on Acorda Therapeutics Inc's stock as an investment opportunity:

Acorda Therapeutics Inc (ACOR) Stock Price | Nasdaq
Acorda Therapeutics Inc (ACOR) Stock Quote, History and News - Yahoo Finance
Acorda Therapeutics Inc (ACOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6933 seconds.